Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 08/25 10:00:14 pm
62.32 USD   -0.65%
08/25 INSIDE THE FDA : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSm..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitio..
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisiti..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
08/25 INSIDE THE FDA EBOLA EDITION : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoS..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/17 DOW MOVERS : Csco, pfe
08/17 INVESTORSOBSERVER : releases covered-call reports for NVIDIA, Dicks Sporting Goo..
08/11 MERCK : Findings from Merck & Company in the Area of Medicinal Chemistry Reporte..
08/10 MERCK : Amica Mutual Insurance Co Lowers stake in Merck & Co. (MRK)
08/09DJMARKET SNAPSHOT : Stocks March Higher, Buoyed By Health-care, Consumer-staples G..
08/09 DOW MOVERS : Mrk, gs
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
More news
Sector news : Pharmaceuticals - NEC
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Merck Offers Value, Yield, And Reliable Dividends
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/23 Ships And Ports Topside For Industrial Sector In August
08/23 Who's Next After Medivation?
08/22 Pfizer Pays Up
Advertisement
Financials ($)
Sales 2016 39 681 M
EBIT 2016 13 578 M
Net income 2016 5 853 M
Debt 2016 4 707 M
Yield 2016 2,97%
P/E ratio 2016 30,25
P/E ratio 2017 20,60
EV / Sales 2016 4,46x
EV / Sales 2017 4,40x
Capitalization 172 328 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 65,5 $
Spread / Average Target 5,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.17.99%173 462
JOHNSON & JOHNSON15.43%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.62%213 882
PFIZER INC.7.71%211 206
GLAXOSMITHKLINE PLC21.19%106 869
More Results